Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 14803 + peginterferon alfa + ribavirin
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
ISIS 14803 + peginterferon alfa + ribavirin is a combination therapy investigated for the treatment of chronic hepatitis C virus (HCV) infection, particularly in patients who have not responded adequately to standard therapy with peginterferon alfa and ribavirin alone. ISIS 14803 is an experimental antisense phosphorothioate oligodeoxynucleotide that targets the translation initiation region of the HCV internal ribosome entry site (IRES), inhibiting viral protein expression by binding to viral RNA and inducing RNase H-mediated cleavage. Peginterferon alfa is a recombinant interferon that induces innate immune responses against HCV, while ribavirin is a nucleoside analog antiviral agent. The combination was studied in Phase 1/2 clinical trials to assess safety, tolerability, and antiviral activity in chronic hepatitis C patients with poor response to standard therapy[1][2][5][6].
- Other names
- peginterferon alfaribavirin
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)HCV IRES (Hepatitis C virus internal ribosome entry site)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on ISIS 14803 + peginterferon alfa + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 14803 + peginterferon alfa + ribavirin.